Trial Profile
A Phase IB Study of Sorafenib for Patient With Locally Advanced or Metastatic Hepatocellular Carcinoma and Child's B Cirrhosis.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Pharmacokinetics
- 22 May 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 30 Nov 2010 Planned end date changed from 1 Sep 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov
- 30 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov